Aequus Pharmaceuticals (TSX-V: AQS, OTCQB: AQSZF) is a rapidly growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ sales and marketing efforts are based in Canada, targeting highly specialized therapeutic areas including neurology, ophthalmology and transplant. Aequus is developing a pipeline of products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada and to establish strategic partnerships to accelerate and maximize the potential of its product candidates worldwide.

Aequus is developing a pipeline of prescription medications in neurology and psychiatry and that address current delivery and compliance challenges....

More

Aequus’ management team has a proven track record of managing clinical development, regulatory approval, product launches, and marketing products both directly and through partnerships....

More

Stock Info

Symbol
Exchange
Price
Change (%)
AQS
TSX-V
$0.00
+0.02 (0%)
Data as of
Minimum 20 minute delay
Symbol
Exchange
Price
Change (%)
AQSZF
OTCQB
$0.00
+0.02 (0%)
Data as of
Minimum 20 minute delay

Latest News

Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba

Aequus Provides Q3 2016 Financial Highlights with Substantial Increase in Quarter over Quarter Revenues

All News

E-News Subscription